Competition in the CGRP migraine space has left both Teva and Amgen willing to take hits on sales to hook new patients.
Filgotinib delivers an important win in its first pivotal rheumatoid arthritis study, setting partners Gilead and Galapagos hot on the heels of Abbvie.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Biopharma might be getting the pricing controls that it tried to stop.
The two companies disagree on the commercial potential of an mRNA flu vaccine, and Biontech just got Pfizer’s buy-in.
Disappointing second-quarter sales of Novo Nordisk's GLP-1 agonists, Victoza and its successor Ozempic, raise questions.